CA2319174A1 - Agents therapeutiques modulant les recepteurs 5-ht - Google Patents

Agents therapeutiques modulant les recepteurs 5-ht Download PDF

Info

Publication number
CA2319174A1
CA2319174A1 CA002319174A CA2319174A CA2319174A1 CA 2319174 A1 CA2319174 A1 CA 2319174A1 CA 002319174 A CA002319174 A CA 002319174A CA 2319174 A CA2319174 A CA 2319174A CA 2319174 A1 CA2319174 A1 CA 2319174A1
Authority
CA
Canada
Prior art keywords
compound
ligand
linker
ligands
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002319174A
Other languages
English (en)
Inventor
Daniel Marquess
John H. Griffin
Seok-Ki Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2319174A1 publication Critical patent/CA2319174A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention porte sur des composés à liaisons multiples. Ces composés comportent de 2 à 10 ligands reliés entre eux par covalence. Chacun de ces ligands est capable d'une liaison avec un récepteur 5-HT, et donc d'en moduler les processus ou les fonctions biologiques.
CA002319174A 1998-06-08 1999-06-07 Agents therapeutiques modulant les recepteurs 5-ht Abandoned CA2319174A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8846698P 1998-06-08 1998-06-08
US60/088,466 1998-06-08
US9293898P 1998-07-15 1998-07-15
US60/092,938 1998-07-15
US9660698P 1998-08-14 1998-08-14
US60/096,606 1998-08-14
PCT/US1999/012751 WO1999064044A1 (fr) 1998-06-08 1999-06-07 Agents therapeutiques modulant les recepteurs 5-ht

Publications (1)

Publication Number Publication Date
CA2319174A1 true CA2319174A1 (fr) 1999-12-16

Family

ID=27375972

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002319174A Abandoned CA2319174A1 (fr) 1998-06-08 1999-06-07 Agents therapeutiques modulant les recepteurs 5-ht

Country Status (6)

Country Link
EP (1) EP1083918A1 (fr)
AR (1) AR019631A1 (fr)
AU (1) AU4425399A (fr)
CA (1) CA2319174A1 (fr)
SG (1) SG83723A1 (fr)
WO (1) WO1999064044A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903996D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
WO2002060375A2 (fr) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Derives d'oxyde de diphenyle et leurs utilisations en tant qu'inhibiteurs de l'heparanase
AU2003297048A1 (en) * 2002-12-13 2004-07-09 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
WO2010123139A1 (fr) * 2009-04-24 2010-10-28 持田製薬株式会社 Dérivé arylcarboxamide ayant un groupe sulfamoyle
RS57618B1 (sr) * 2013-08-02 2018-11-30 Pfizer Heterobicikloaril rorc2 inhibitori i postupci za njihovu upotrebu
US10485789B2 (en) 2014-07-24 2019-11-26 Sensor Pharmaceuticals, Inc. Compositions and methods for targeting receptors expressed in the gut
CN105439914B (zh) * 2014-09-17 2017-07-11 复旦大学 4‑氨酰基苯氧乙酰胺类化合物及其药物用途
EP3250561A1 (fr) 2015-01-30 2017-12-06 Pfizer Inc Modulateurs indole de rorc2 substitués par sulfonamide et leurs procédés d'utilisation
WO2016120849A1 (fr) 2015-01-30 2016-08-04 Pfizer Inc. Modulateurs de pyrrolopyridine substituée par un méthoxy de rorc2 et leurs méthodes d'utilisation
MX2023002619A (es) * 2020-09-02 2023-04-10 Enveric Biosciences Canada Inc Derivados nitrados de psilocibina y uso de los mismos para modular el receptor 5-ht2a y para tratar un trastorno psiquiatrico.
WO2023044556A1 (fr) * 2021-09-24 2023-03-30 Enveric Biosciences Canada Inc. Dérivés de psilocybine aminés et procédés d'utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
US5244912A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof
FR2712591B1 (fr) * 1993-11-19 1996-02-09 Pf Medicament Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
AU2332497A (en) * 1996-03-19 1997-10-10 Salk Institute For Biological Studies, The (in vitro) methods for identifying modulators of members of the steroid/thyroid superfamily of receptors
US6500934B1 (en) * 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
WO1998011436A1 (fr) * 1996-09-13 1998-03-19 Whitehead Institute For Biomedical Research Augmentation de l'affinite non specifique pour identifier des membres d'une bibliotheque combinatoire
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives

Also Published As

Publication number Publication date
AR019631A1 (es) 2002-02-27
WO1999064044A1 (fr) 1999-12-16
EP1083918A1 (fr) 2001-03-21
SG83723A1 (en) 2001-10-16
AU4425399A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
US6693202B1 (en) Muscarinic receptor antagonists
US6355805B1 (en) β3-adrenergic receptor agonists
EP1083920A1 (fr) Composes antibacteriens
US6395724B1 (en) Multibinding inhibitors of cyclooxygenase-2
AU4672699A (en) Novel sodium channel drugs and uses
WO1999063984A9 (fr) Nouveaux medicaments des canaux sodiques et utilisations
CA2319174A1 (fr) Agents therapeutiques modulant les recepteurs 5-ht
EP1086066A1 (fr) Antagonistes des recepteurs muscariniques
US6420560B1 (en) H1—histamine receptor antagonists
EP1085895A1 (fr) Antagonistes de bradykinine
AU4426499A (en) Novel potassium channel drugs and their uses
ZA200004083B (en) H1-histamine receptor antagonists.
ZA200004564B (en) Novel potassium channel drugs and their uses.

Legal Events

Date Code Title Description
FZDE Dead